Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10378642" target="_blank" >RIV/00216208:11110/18:10378642 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/18:10378642

Výsledek na webu

<a href="https://doi.org/10.2174/1567205015666180601090533" target="_blank" >https://doi.org/10.2174/1567205015666180601090533</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1567205015666180601090533" target="_blank" >10.2174/1567205015666180601090533</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease

Popis výsledku v původním jazyce

Background: Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the epsilon 4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. Objective: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. Method: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. Results: A significant association between AD and the allele (epsilon 4) or genotype (epsilon 3/epsilon 4 or epsilon 4/epsilon 4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE epsilon 4 allele, regardless of the presence of depression or the severity of dementia in AD. Conclusion: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE epsilon 4 allele.

Název v anglickém jazyce

Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease

Popis výsledku anglicky

Background: Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the epsilon 4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. Objective: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. Method: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. Results: A significant association between AD and the allele (epsilon 4) or genotype (epsilon 3/epsilon 4 or epsilon 4/epsilon 4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE epsilon 4 allele, regardless of the presence of depression or the severity of dementia in AD. Conclusion: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE epsilon 4 allele.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/GA17-05292S" target="_blank" >GA17-05292S: Nové krevní biomarkery pro včasnou diagnostiku, prognózu a průběh Alzheimerovy nemoci</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Alzheimer Research

ISSN

1567-2050

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

13

Strana od-do

938-950

Kód UT WoS článku

000442171000005

EID výsledku v databázi Scopus

2-s2.0-85051840048